Compare Adaptive Biotechnologies Corp (ADPT) vs Motorola Solutions Inc (MSI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Motorola Solutions Inc — how do they compare? Adaptive Biotechnologies Corp trades at $19.96 (market cap $3.33B), while Motorola Solutions Inc trades at $419.53 (market cap $70.42B). The key difference: Motorola Solutions Inc is far larger — about 21.1× Adaptive Biotechnologies Corp's market cap, and Motorola Solutions Inc pays a 1.14% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | MSI | |
|---|---|---|
Market Cap | $3.33B | $70.42B |
Sector | Health | Technology |
52-Week High | $22.37 | $490.30 |
52-Week Low | $10.24 | $363.83 |
Enterprise Value | $3.19B | $79.12B |
Dividend Yield | — | 1.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Motorola Solutions (MSI) trades at $424.21, up 0.37% with strong technical momentum and bullish analyst sentiment. The company demonstrates robust fundamentals with 17.61% net margins and consistent earnings beats, supported by recent AI expansion initiatives and a $1.5B acquisition of D-Fend Solutions. Revenue growth has accelerated from $9.1B in 2022 to $11.7B in 2025.
MSI presents a compelling growth story with AI-driven public safety expansion and strong institutional support, though elevated valuation multiples and increased capital expenditures pose risks. The consensus price target of $512.33 suggests 21% upside potential, supported by 71% analyst buy ratings and positive technical indicators.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Motorola Solutions Inc
Motorola Solutions, Inc. is a data communications and telecommunications equipment provider. The Company develops data capture, wireless, infrastructure, bar code scanning, two-way radios, and wireless broadband networks. Motorola also produces public safety and government products, voice and data communications products and systems, and wireless LAN securities.
Read more on MSI →
